Key Takeaways
- CAH will report Q3 fiscal 2026 earnings on April 30; estimates call for $62.4B sales and $2.81 EPS.
- CAH’s specialty business is poised to exceed $50B in fiscal 2026, led by oncology and biopharma services.
- Existing holders may stay put, while new investors may wait for results and updated commentary.
Cardinal Health (CAH – Free Report) is set to report third-quarter fiscal 2026 earnings on April 30. The Zacks Consensus Estimate for sales and earnings is pegged at $62.4 billion and $2.81 per share, respectively. Earnings per share (EPS) estimates for CAH have improved 1 cent to $10.32 for 2026 and 2 cents to $11.59 for 2027 over the…
